Historical record - last NADAC effective date: 10/23/2019
Product Information
LAMIVUDINE 150 MG TABLET is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $0.9893 per EA under NDC 50742062360. Its NADAC has been published 114 times since Oct 4, 2017.
FDA first approved this application on Nov 21, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742062360
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
10/23/2019
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA206974FDA Approved
11/21/2016
TE Code
AB
On Market Since
2/1/2017
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 150 MG TABLET has been published 114 times since Oct 4, 2017, and over the history we have for it it has declined 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9893 per EA |
|---|---|
| All-time high | $1.5942 (Jan 10, 2018) |
| All-time low | $0.7071 (Mar 20, 2019) |
| Median price | $1.1873 |
| Average price | $1.1844 |
| Largest weekly change | +54.1% (May 22, 2019) |
| Weeks tracked | 114 |
| Tracking since | Oct 4, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-32.4%
Last surveyed Dec 4, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 52% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ingenus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 150 MG TABLET, manufactured by Ingenus Pharmaceuticals LLC, is $0.9893 per EA (NDC 50742062360), effective Dec 4, 2019.
How has the price of LAMIVUDINE 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 150 MG TABLET has declined 32.4%. It has been tracked across 114 weekly CMS publications since Oct 4, 2017.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 150 MG TABLET?
Since Oct 4, 2017, the NADAC for LAMIVUDINE 150 MG TABLET has ranged from a low of $0.7071 (Mar 20, 2019) to a high of $1.5942 (Jan 10, 2018), with a median of $1.1873 per EA.
Are there cheaper alternatives to LAMIVUDINE 150 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE 150 MG TABLET, is $0.4797 per EA — about 52% below LAMIVUDINE 150 MG TABLET.
Who manufactures LAMIVUDINE 150 MG TABLET?
LAMIVUDINE 150 MG TABLET (NDC 50742062360) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.